Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00744965 |
Recruitment Status
:
Completed
First Posted
: September 1, 2008
Last Update Posted
: January 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mild Gestational Diabetes | Drug: Glyburide Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 395 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo |
Study Start Date : | August 2008 |
Actual Primary Completion Date : | January 2013 |
Actual Study Completion Date : | January 2016 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
|
Drug: Glyburide
Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
|
Placebo Comparator: 2
Women with mild gestational diabetes will be started ADA diet and placebo.
|
Drug: Placebo
Sham dose adjustments of the placebo will be made.
|
- Fetal weight reduction of 200gm with Glyburide treatment [ Time Frame: Immediately after delivery of fetus ]
- Large for gestational age infants [ Time Frame: After delivery ]
- Macrosomia [ Time Frame: After delivery ]
- Neonatal Intensive Care Unit admissions [ Time Frame: Until hospital discharge ]
- Rate of cesarean delivery [ Time Frame: After delivery ]
- Risk of preeclampsia [ Time Frame: until hospital discharge ]
- Time to achieve glycemic control [ Time Frame: after delivery ]
- Need for insulin treatment [ Time Frame: after delivery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 45 Years (Child, Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- A glucose value of ≥140 mg/dl on a 50-gram oral glucose loading test by plasma at gestational age between 24 weeks 0 days and 27 weeks 6 days based on clinical information
- An Abnormal 3-hour oral glucose tolerance test with a fasting glucose of ≤105 mg/dl
- Gestational age of less than or equal to 28 weeks and 0 days at the time of consent/randomization
- Singleton gestation
Exclusion Criteria:
- Established pregestational diabetes
- Abnormal gestational diabetes testing (≥140) prior to 24 weeks 0 days of gestation. Women who have a negative glucose loading test (<140mg/dl) before 24 weeks may still be considered for this study if they present again for glucose tolerance testing between 24 and 27 weeks.
- Multiple gestations
- Known major fetal anomaly or fetal demise
- Any renal disease with serum creatinine of >1.0
- Known liver disease such as hepatitis
- Maternal or fetal conditions likely to require imminent or very preterm delivery such as preeclampsia, preterm premature rupture of the membranes, preterm labor, and intrauterine fetal growth restriction
- Known hypersensitivity or allergic reaction to Glyburide

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00744965
United States, Texas | |
Parkland Memorial Hospital | |
Dallas, Texas, United States, 75235 |
Publications of Results:
Responsible Party: | Brian Casey, Professor, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT00744965 History of Changes |
Obsolete Identifiers: | NCT00942552 |
Other Study ID Numbers: |
032011-086 042008-058 ( Other Identifier: UTexasSouthwestern ) |
First Posted: | September 1, 2008 Key Record Dates |
Last Update Posted: | January 26, 2017 |
Last Verified: | January 2017 |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes, Gestational Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Pregnancy Complications Glyburide Hypoglycemic Agents Physiological Effects of Drugs |